Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 261

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Long-term Survival and Toxicity in Patients Treated With High-Dose Intensity Modulated Radiation Therapy for Localized Prostate Cancer

Open access
Spratt, Daniel E., Pei, Xin, Yamada, Josh, Kollmeier, Marisa A., Cox, Brett, Zelefsky, Michael J. · 2013 · International Journal of Radiation Oncology*Biology*Physics

Abstract

Summary We report long-term outcomes on 1002 patients treated to 8640 cGy for localized prostate cancer using IMRT. High dose-escalation results in excellent tumor control with minimal toxicity when implementing strict dose constraints. Dose-escalation beyond 80 Gy is feasible and safe, and should be considered for select men with localized prostate cancer. Purpose To report the long-term survival and toxicity outcomes with the use of high dose intensity modulated radiation therapy (IMRT) to 86.4 Gy for patients with localized prostate cancer. Materials and Methods Between August 1997 and December 2008, 1002 patients were treated to a dose of 86.4 Gy using a 5–7 field IMRT technique. Patients were stratified into prognostic risk groups based on the National Comprehensive Cancer Network risk classification criteria. Five hundred eighty-seven patients (59%) were treated with neoadjuvant and concurrent androgen deprivation therapy (ADT). The median follow-up for the entire cohort was 5.5 years (range, 1–14 yrs). Results For low-, intermediate- and high-risk groups the 7-year biochemical relapse-free survival outcomes were 98.8%, 85.6%, and 67.9% (p<0.001), and distant metastasis-free survival rates of 99.4%, 94.1%, and 82.0% (p<0.001), respectively. On multivariate analysis T-stage (p<0.001), Gleason score (p<0.001), and >50% of initial biopsy cores positive (p=0.001) were predictive for DM. No prostate cancer related deaths were observed in the low-risk group. The 7-year prostate cancer–specific mortality (PCSM) using competing risk analysis for intermediate- and high-risk groups was 3.3% and 8.1%, respectively (p=0.008). On multivariate analysis Gleason score (p=0.004), percent biopsy core positivity (p=0.003), and T-stage (p=0.033) were predictive for PCSM. Actuarial 7-year grade 2 or higher late gastrointestinal and genitourinary toxicities were 4.4% and 21.1%, respectively. Late grade 3 gastrointestinal and genitourinary toxicity was experienced by 7 patients (0.7%) and 22 patients (2.2%), respectively. Of the 427 men with full potency at baseline, 317 men (74%) retained sexual function at time of last follow-up. Conclusions This represents the largest cohort of patients treated with high dose radiation to 86.4 Gy using IMRT for localized prostate cancer with the longest follow-up to date. Our findings indicate that this treatment results in excellent clinical outcomes with acceptable toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ijrobp.2012.05.023

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 261

Metadata

Authors
Spratt, D. E., Pei, X., Yamada, J., Kollmeier, M. A., Cox, B., & Zelefsky, M. J.
Venue
International Journal of Radiation Oncology*Biology*Physics
Publisher
Elsevier BV
Published
2013-03
Volume
85
Issue
3
Pages
686-692
ISSN
0360-3016 (ISSN-L)
OpenAlex
W2127755970
Cited by
261
References
16
FWCI
22.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.